Journal
PEDIATRIC DERMATOLOGY
Volume 38, Issue 3, Pages 714-716Publisher
WILEY
DOI: 10.1111/pde.14590
Keywords
childhood; ichthyosis; ı nfliximab; Netherton Syndrome; tumor necrosis factor‐ a
Categories
Ask authors/readers for more resources
Infliximab shows promising efficacy in patients with Netherton syndrome, and significant clinical improvement can be observed even in infants.
We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6 months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12 months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available